Cure8 research brief
A simple blood marker (LBP) that reflects bacterial exposure across the gut barrier was linked to disease severity and immune activity at diagnosis and during follow-up—especially in ulcerative colitis—so it might help monitor mucosal inflammation alongside existing tests.
This is potentially relevant for pediatric patients and clinicians tracking disease activity.
Pediatric IBD patients and caregivers; gastroenterology clinicians; researchers interested in biomarkers, intestinal permeability, and immune pathways in IBD.
This paper reports that plasma lipopolysaccharide-binding protein (LBP), an indirect blood biomarker reflecting systemic exposure to bacterial endotoxin (used here as a proxy for intestinal permeability), was measured longitudinally in a large, newly diagnosed pediatric IBD cohort.
LBP levels were higher in treatment‑naive Crohn’s disease and ulcerative colitis patients and were associated with clinicopathological and immune activity measures at diagnosis and over follow-up.
In ulcerative colitis, LBP showed particularly strong independent correlations with disease extent and with endoscopic and histologic activity, adding explanatory value beyond common blood markers (for example CRP and IL‑6). LBP also tracked with disease‑specific immune protein profiles (IL‑17/neutrophil/IFN‑γ pattern in UC; IFN‑γ pattern in CD).
LBP decreased after certain induction therapies: corticosteroids in UC, and exclusive enteral nutrition or anti‑TNF in CD (but not after corticosteroids in CD). The authors conclude LBP could be reconsidered as a simple, inexpensive adjunctive blood marker for monitoring mucosal inflammation—especially in UC.
Abstract-level summary from the Journal of Crohn’s & Colitis; findings are from pediatric cohorts and use LBP as an indirect biomarker of permeability. This does not itself establish LBP as a validated clinical monitoring tool across all settings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Biopsy-based keratin patterns might help distinguish IBD, microscopic colitis, and IBS—conditions that can look similar clinically—so this could improve diagnostic accuracy if validated.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...
